Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ME Therapeutics Holdings, Inc. ( (TSE:METX) ) has provided an update.
ME Therapeutics has secured exclusive commercial rights to a nanobody-based CD22 binder from the National Research Council of Canada, enhancing their next-generation CAR cell therapy program. This strategic move aims to develop innovative treatments for relapsed/refractory B-cell cancers, potentially improving the company’s market position in immuno-oncology by leveraging advanced nanobody technology.
More about ME Therapeutics Holdings, Inc.
ME Therapeutics Holdings Inc. is a publicly listed biotechnology company based in Vancouver, focusing on novel cancer-fighting drugs in the field of immuno-oncology.
Average Trading Volume: 834
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$121.3M
See more data about METX stock on TipRanks’ Stock Analysis page.